212 related articles for article (PubMed ID: 20513033)
1. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
3. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.
García-Carracedo D; Villaronga MÁ; Álvarez-Teijeiro S; Hermida-Prado F; Santamaría I; Allonca E; Suárez-Fernández L; Gonzalez MV; Balbín M; Astudillo A; Martínez-Camblor P; Su GH; Rodrigo JP; García-Pedrero JM
Oncotarget; 2016 May; 7(20):29780-93. PubMed ID: 27119232
[TBL] [Abstract][Full Text] [Related]
4. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
6. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Amornphimoltham P; Sriuranpong V; Patel V; Benavides F; Conti CJ; Sauk J; Sausville EA; Molinolo AA; Gutkind JS
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4029-37. PubMed ID: 15217935
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma.
Georgy SR; Cangkrama M; Srivastava S; Partridge D; Auden A; Dworkin S; McLean CA; Jane SM; Darido C
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26063791
[TBL] [Abstract][Full Text] [Related]
9. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Liu F; Zhao X; Qian Y; Zhang J; Zhang Y; Yin R
Biomed Pharmacother; 2017 Dec; 96():229-237. PubMed ID: 28987947
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.
Molinolo AA; Hewitt SM; Amornphimoltham P; Keelawat S; Rangdaeng S; Meneses García A; Raimondi AR; Jufe R; Itoiz M; Gao Y; Saranath D; Kaleebi GS; Yoo GH; Leak L; Myers EM; Shintani S; Wong D; Massey HD; Yeudall WA; Lonardo F; Ensley J; Gutkind JS
Clin Cancer Res; 2007 Sep; 13(17):4964-73. PubMed ID: 17785546
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.
Schneider A; Younis RH; Gutkind JS
Neoplasia; 2008 Nov; 10(11):1295-302. PubMed ID: 18953439
[TBL] [Abstract][Full Text] [Related]
13. Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation.
Chang JW; Jung SN; Kim JH; Shim GA; Park HS; Liu L; Kim JM; Park J; Koo BS
Sci Rep; 2016 Jun; 6():28503. PubMed ID: 27328758
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma.
Moral M; Segrelles C; Martínez-Cruz AB; Lorz C; Santos M; García-Escudero R; Lu J; Buitrago A; Costa C; Saiz C; Ariza JM; Dueñas M; Rodriguez-Peralto JL; Martinez-Tello FJ; Rodriguez-Pinilla M; Sanchez-Cespedes M; Digiovanni J; Paramio JM
In Vivo; 2009; 23(5):653-60. PubMed ID: 19779097
[TBL] [Abstract][Full Text] [Related]
15. Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Lin CL; Chiang WF; Tung CL; Hsieh JL; Hsiao JR; Huang WT; Feng LY; Chang CH; Liu SY; Tsao CJ; Feng YH
Mol Med Rep; 2015 Jan; 11(1):547-54. PubMed ID: 25333206
[TBL] [Abstract][Full Text] [Related]
16. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
17. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway.
Hu J; Li G; Liu Z; Ma H; Yuan W; Lu Z; Zhang D; Ling H; Zhang F; Liu Y; Liu C; Qiu Y
Mol Carcinog; 2023 May; 62(5):628-640. PubMed ID: 36727616
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma.
Freudlsperger C; Horn D; Weißfuß S; Weichert W; Weber KJ; Saure D; Sharma S; Dyckhoff G; Grabe N; Plinkert P; Hoffmann J; Freier K; Hess J
Int J Cancer; 2015 Jun; 136(12):2775-85. PubMed ID: 25388642
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
Vander Broek R; Mohan S; Eytan DF; Chen Z; Van Waes C
Oral Dis; 2015 Oct; 21(7):815-25. PubMed ID: 24219320
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
